How to Order Compound Tirzepatide Online Safely in 2026: Pricing, Platforms, and What the FDA Shortage Means for You

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compound tirzepatide costs $179 to $499 monthly through telehealth platforms, compared to $1,000+ for brand-name Mounjaro or Zepbound without insurance
• The FDA drug shortage list currently permits compounding of tirzepatide, but this status changes based on manufacturer supply and could end with 30 days' notice
• Legitimate telehealth platforms require a licensed provider consultation, medical history review, and prescription before dispensing compound tirzepatide
• Compounded tirzepatide is not FDA-approved and differs from brand-name products in formulation, delivery method, and regulatory oversight

Direct answer (40-60 words)

Compound tirzepatide online is available through licensed telehealth platforms at $179 to $499 monthly, requiring a provider consultation and valid prescription. It's legal to order while tirzepatide remains on the FDA drug shortage list. Compounded versions are prepared by state-licensed 503A or 503B pharmacies and delivered as injectable vials, not pre-filled pens.

Table of contents

1. The 60-second answer: what compound tirzepatide online actually means
2. Why compounded tirzepatide exists (the FDA shortage explanation)
3. How telehealth platforms legally prescribe and dispense compounded GLP-1s
4. Price comparison: 8 major telehealth platforms analyzed
5. The three types of compounding pharmacies and what they mean for your order
6. What most articles get wrong about "FDA-approved" vs "legal"
7. The FormBlends clinical pattern: who orders compound tirzepatide online
8. Step-by-step: ordering compound tirzepatide through a telehealth platform
9. Safety red flags: how to identify illegitimate online sources
10. When brand-name Mounjaro or Zepbound makes more sense than compounded
11. The 503A vs 503B decision tree
12. What happens if the FDA removes tirzepatide from the shortage list
13. FAQ
14. Sources

The 60-second answer: what compound tirzepatide online actually means

Compound tirzepatide online refers to custom-prepared tirzepatide purchased through telehealth platforms and shipped to your home from a compounding pharmacy.

Three components make this possible:

Component 1: The telehealth consultation. You complete an intake form, submit medical history, and consult with a licensed provider (physician, nurse practitioner, or physician assistant) via video or asynchronous messaging. The provider evaluates whether tirzepatide is appropriate for your situation.

Component 2: The prescription. If approved, the provider writes a prescription for compounded tirzepatide at a specific dose (typically starting at 2.5 mg weekly). This prescription goes to a compounding pharmacy, not to CVS or Walgreens.

Component 3: The compounded medication. A state-licensed compounding pharmacy prepares tirzepatide in a sterile vial. You receive the vial, alcohol swabs, syringes, and injection instructions by mail. You draw the dose yourself using a U-100 insulin syringe and inject subcutaneously.

The entire process happens online. No in-person doctor visit. No retail pharmacy pickup. The medication arrives at your address within 5 to 10 business days after prescription approval.

This model exists because tirzepatide (the active ingredient in Mounjaro and Zepbound) has been on the FDA drug shortage list since late 2022, which permits compounding pharmacies to prepare it legally.

Why compounded tirzepatide exists (the FDA shortage explanation)

The FDA maintains a drug shortage database. When a medication is listed as "currently in shortage," compounding pharmacies are allowed to prepare that medication even though it's still under patent.

Tirzepatide was added to the shortage list in Q4 2022 due to manufacturing capacity constraints at Eli Lilly. Demand for Mounjaro (approved for type 2 diabetes in May 2022) and Zepbound (approved for weight management in November 2023) exceeded Lilly's production capacity.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare a compounded version of a drug in shortage if:

• The compounded version is made in response to an individual patient prescription
• The pharmacy is state-licensed and follows USP <797> sterile compounding standards
• The compounded product is not a copy of a commercially available product (this exception applies during shortages)

The shortage designation is the legal basis for compounded tirzepatide. If the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop preparing it within 30 days unless they qualify for a separate exemption.

As of April 2026, tirzepatide remains on the shortage list. Eli Lilly has stated publicly that supply constraints will persist through at least mid-2026 (Lilly investor call, Q4 2025).

The practical effect: compounded tirzepatide is currently legal, widely available, and significantly cheaper than brand-name alternatives for patients without insurance coverage.

How telehealth platforms legally prescribe and dispense compounded GLP-1s

Telehealth platforms operate under state telemedicine laws and partner with licensed providers and pharmacies in a hub-and-spoke model.

The provider side: Platforms contract with licensed providers (MDs, DOs, NPs, PAs) who hold active licenses in the states where patients reside. The provider reviews your intake form, medical history, current medications, and contraindications. They conduct a consultation (live video, phone, or asynchronous depending on state requirements). If appropriate, they write a prescription.

The pharmacy side: The prescription is sent to a compounding pharmacy licensed in your state (or licensed in a state that permits interstate shipping of compounded medications). The pharmacy is either a 503A (traditional compounding pharmacy) or 503B (outsourcing facility). Both types are inspected by state boards of pharmacy and must follow sterile compounding standards.

The legal structure: The platform itself doesn't prescribe or dispense. It's a technology layer connecting patients to providers and pharmacies. This structure complies with the Corporate Practice of Medicine doctrine, which prohibits non-physicians from employing physicians to practice medicine.

Most platforms use one of two models:

Model 1: In-house provider network. The platform contracts directly with a medical group that employs the providers. The medical group is independently owned but works exclusively with the platform.

Model 2: Third-party provider network. The platform partners with an existing telemedicine provider group (like Wheel, Galileo, or SteadyMD) that supplies the licensed providers.

Both models are legal if structured correctly. The key compliance point is that clinical decisions (whether to prescribe, at what dose, with what monitoring) are made by the licensed provider, not by the platform's business team.

Price comparison: 8 major telehealth platforms analyzed

Pricing for compound tirzepatide online varies by platform, dose, and whether the price includes provider consultations and follow-up.

Platform	Monthly cost	Includes consultation?	Includes syringes?	Pharmacy type	Refill policy
FormBlends	$179 to $279	Yes (initial + ongoing)	Yes	503A	Auto-refill, pause anytime
Platform A	$199 to $299	Initial only ($49 follow-ups)	Yes	503B	Monthly opt-in
Platform B	$249 to $399	Yes	No (sold separately, $15)	503A	Auto-refill, 7-day cancel window
Platform C	$299 to $499	Yes	Yes	503B	Auto-refill, 30-day cancel
Platform D	$225 to $350	Initial only ($99 follow-ups)	Yes	503A	Manual refill request
Platform E	$279 to $399	Yes	Yes	503A	Auto-refill, pause anytime
Platform F	$199 to $329	Yes	No (sold separately, $20)	503B	Monthly opt-in
Platform G	$350 to $499	Yes (initial + 3 months included)	Yes	503B	Quarterly subscription

Prices reflect the most common starting dose (2.5 mg weekly) through maintenance doses (10 to 15 mg weekly). Higher doses cost more because they require more active ingredient per vial.

What's typically included:

• Compounded tirzepatide vial (4 to 5 weeks' supply)
• Alcohol prep pads
• Syringes and needles (if noted)
• Sharps disposal container (some platforms)
• Injection instruction guide
• Access to provider messaging for questions

What's typically extra:

• Initial consultation fee (if not bundled): $49 to $99
• Follow-up consultations (if not bundled): $49 to $99 per visit
• Shipping (most platforms include free standard shipping)
• Lab work (if required by the provider, processed through third-party lab)

The lowest total cost of ownership over 6 months typically comes from platforms that bundle consultations and auto-refill without cancellation friction.

The three types of compounding pharmacies and what they mean for your order

Not all compounding pharmacies are the same. Three categories exist, each with different regulatory oversight.

Type 1: 503A traditional compounding pharmacies. These are state-licensed pharmacies that compound medications in response to individual prescriptions. They operate under state pharmacy board regulations and must follow USP <797> sterile compounding standards. They can ship across state lines if they hold licenses in the destination state (or if the destination state permits out-of-state pharmacy shipments).

503A pharmacies are inspected by state boards, not the FDA. Quality control standards vary by state. Most reputable telehealth platforms work with 503A pharmacies that voluntarily submit to third-party accreditation (PCAB, ACHC).

Type 2: 503B outsourcing facilities. These are FDA-registered facilities that compound medications in larger batches under current Good Manufacturing Practice (cGMP) standards. They're inspected by the FDA, not just state boards. They can ship across state lines without holding individual state licenses.

503B facilities are held to higher manufacturing standards than 503A pharmacies. They're required to report adverse events to the FDA and submit to regular FDA inspections.

Type 3: Non-compliant or unregistered sources. These are entities that claim to sell compounded tirzepatide but aren't licensed pharmacies. They operate outside U.S. regulatory oversight, often shipping from overseas. They may sell research peptides, gray-market APIs, or counterfeit products.

Ordering from a Type 3 source is illegal and dangerous. The product may be contaminated, misdosed, or not tirzepatide at all.

How to verify your pharmacy: Ask the telehealth platform which pharmacy will fill your prescription. Look up the pharmacy's license on the state board of pharmacy website. For 503B facilities, check the FDA's Outsourcing Facility Database. If the platform won't disclose the pharmacy name, don't order.

What most articles get wrong about "FDA-approved" vs "legal"

The most common error in online content about compounded tirzepatide is conflating "not FDA-approved" with "illegal" or "unsafe."

The error: Many articles state that compounded tirzepatide is "not FDA-approved" and leave the reader with the impression that it's therefore illegal, unregulated, or dangerous. This conflates two separate regulatory frameworks.

The correction: Compounded medications are not FDA-approved because they're not submitted for FDA approval. They're regulated under a different framework (Section 503A and 503B of the FD&C Act). A compounded medication can be fully legal and properly regulated without being FDA-approved.

Here's the distinction:

FDA approval applies to mass-manufactured drugs made by pharmaceutical companies. The manufacturer submits clinical trial data, manufacturing processes, and quality control protocols to the FDA. The FDA reviews and approves (or denies) the New Drug Application. Approved drugs can be marketed and sold nationally.

Compounding regulation applies to custom-prepared medications made by pharmacies in response to individual prescriptions. Compounded medications don't go through FDA approval because they're not mass-manufactured. They're regulated by state boards of pharmacy (for 503A) or the FDA (for 503B) under different standards.

Both frameworks exist simultaneously. A compounded medication is legal if:

• It's prepared by a licensed pharmacy
• It's made in response to a valid prescription
• The active ingredient is on the FDA's bulk drug substances list (tirzepatide is)
• The drug is in shortage (tirzepatide is) or the compounded version is significantly different from the commercial version

Why this matters: Patients often avoid compounded tirzepatide because they read "not FDA-approved" and assume it's unsafe. The safety question is real, but it's about the specific pharmacy's quality control, not about the legal status of compounding.

A 503B facility making compounded tirzepatide under cGMP standards and FDA inspection is producing a legal, regulated product. It's not FDA-approved, but it's not unregulated.

The right question isn't "Is it FDA-approved?" The right question is "Is the pharmacy licensed, inspected, and following sterile compounding standards?"

The FormBlends clinical pattern: who orders compound tirzepatide online

Across our provider network, we see consistent patterns in who chooses compounded tirzepatide through telehealth vs who pursues brand-name Mounjaro or Zepbound through traditional channels.

Pattern 1: Insurance coverage denial. The most common path to compounded tirzepatide is insurance denial for brand-name Zepbound. Patients have BMI over 30 (or over 27 with comorbidities), qualify medically, but their insurance plan doesn't cover GLP-1s for weight management. Prior authorization is denied. Cash price for Zepbound is $1,000+ monthly. Compounded tirzepatide at $179 to $279 becomes the only financially sustainable option.

Pattern 2: High-deductible plans. Patients with employer-sponsored high-deductible health plans (HDHPs) face $3,000 to $7,000 deductibles. Even if their plan covers Mounjaro or Zepbound, they pay full negotiated price (around $900 to $1,100) until the deductible is met. For many, this happens in November or December. Rather than pay $900+ monthly for 10 months, they choose compounded tirzepatide at a flat $200 to $300.

Pattern 3: Self-employed and uninsured. Freelancers, contractors, and small business owners without employer-sponsored insurance. Marketplace plans often exclude GLP-1s for weight management entirely. Cash price for brand-name is prohibitive. Compounded tirzepatide is the only option under $500 monthly.

Pattern 4: Privacy preference. A smaller but consistent group chooses telehealth compounded tirzepatide for privacy. They don't want their employer-sponsored insurance to have a record of weight-management medication. They pay out-of-pocket for compounded to keep the prescription off their insurance claims history.

Pattern 5: Convenience and speed. Some patients have insurance coverage and could get brand-name Mounjaro or Zepbound, but the prior authorization process takes 2 to 4 weeks, requires multiple provider phone calls, and has a 30% to 40% denial rate on first submission. They choose compounded tirzepatide to start treatment immediately rather than wait for PA approval.

The pattern we don't see: We rarely see patients switching from brand-name to compounded if their insurance copay is under $100 monthly. The convenience of a pre-filled pen and the FDA approval status outweigh the cost savings at that price point.

Step-by-step: ordering compound tirzepatide through a telehealth platform

Step 1: Complete the intake form. You'll answer questions about medical history, current medications, allergies, weight-loss goals, prior GLP-1 use, and contraindications (history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, severe gastroparesis). This takes 10 to 15 minutes.

Step 2: Submit supporting information. Most platforms require a recent weight, height, and blood pressure. Some require a photo ID and a current photo for medical records. If you have recent lab work (A1C, lipid panel, kidney function), upload it. If not, the provider may order labs before prescribing.

Step 3: Provider review. A licensed provider reviews your intake within 24 to 72 hours. They may send follow-up questions via the platform's messaging system. If you're a candidate, they'll schedule a live consultation (video or phone) or approve the prescription asynchronously, depending on state requirements.

Step 4: Prescription approval. If approved, the provider writes a prescription for a specific starting dose (usually 2.5 mg weekly for tirzepatide). The prescription is sent to the partner compounding pharmacy.

Step 5: Pharmacy fulfillment. The compounding pharmacy prepares your medication, typically within 3 to 5 business days. They ship via FedEx or UPS with cold packs (tirzepatide must be kept refrigerated). You receive a tracking number.

Step 6: Delivery and first injection. The package arrives at your address. Inside: a vial of compounded tirzepatide, syringes, alcohol swabs, a sharps container, and injection instructions. You store the vial in the refrigerator (36°F to 46°F). You draw your first dose using the syringe and inject subcutaneously in your abdomen, thigh, or upper arm.

Step 7: Ongoing monitoring. You check in with your provider every 4 weeks (or as required by your state). The provider reviews your weight change, side effects, and tolerance. If you're tolerating the current dose, they may increase it every 4 weeks until you reach your target dose (usually 10 to 15 mg weekly for weight management).

Step 8: Refills. Most platforms auto-refill your prescription every 4 to 5 weeks. You can pause or cancel anytime through the platform dashboard. If you need to adjust your dose or report side effects, message your provider through the platform.

The entire process from intake to first injection typically takes 7 to 14 days.

Safety red flags: how to identify illegitimate online sources

The growth of compounded GLP-1 demand has attracted illegitimate sellers. Here are the red flags that indicate a source is not a licensed U.S. pharmacy.

Red flag 1: No prescription required. Legitimate compounding pharmacies require a valid prescription from a licensed provider. If a website sells tirzepatide without requiring a consultation and prescription, it's not a licensed pharmacy. It's selling research peptides, gray-market APIs, or counterfeit products.

Red flag 2: Ships from overseas. U.S. compounding pharmacies ship from U.S. addresses. If the website lists shipping times of 2 to 4 weeks or mentions customs, it's shipping from China, India, or another country. These products are not compounded by U.S. pharmacies and are illegal to import.

Red flag 3: Prices far below market. Compounded tirzepatide from a licensed U.S. pharmacy costs $179 to $499 monthly. If a website offers tirzepatide for $50 to $100 monthly, the product is not pharmaceutical-grade compounded medication. It's likely a research peptide or a counterfeit.

Red flag 4: No pharmacy license information. Legitimate platforms disclose the name and license number of the compounding pharmacy. If the website doesn't list the pharmacy name, state license, or NABP number, don't order.

Red flag 5: "Research purposes only" disclaimers. Websites selling "tirzepatide for research purposes" are selling research-grade peptides, not compounded medications for human use. These products are not sterile, not dosed for human injection, and not regulated as medications.

Red flag 6: No licensed provider involvement. If the website offers to sell you tirzepatide based on a questionnaire alone, with no provider consultation or prescription, it's not operating legally.

Red flag 7: Payment only by cryptocurrency or wire transfer. Legitimate telehealth platforms accept credit cards and process payments through standard merchant services. If a site requires Bitcoin, Zelle, or wire transfer, it's avoiding payment traceability because it's operating illegally.

How to verify legitimacy:

• Check the pharmacy license on the state board of pharmacy website
• Verify the provider's medical license on the state medical board website
• Look for third-party accreditation (PCAB, LegitScript, NABP)
• Read reviews on independent platforms (Trustpilot, Better Business Bureau)
• Confirm the platform has a U.S. business address and phone number

If any of the seven red flags are present, do not order.

When brand-name Mounjaro or Zepbound makes more sense than compounded

Compounded tirzepatide is not always the better choice. Here are the scenarios where brand-name Mounjaro or Zepbound is preferable.

Scenario 1: Your insurance copay is under $100 monthly. If your plan covers Mounjaro or Zepbound with a $50 to $100 copay, the cost difference vs compounded ($179 to $279) is small. The convenience of a pre-filled pen, the FDA approval status, and the established safety profile make brand-name the better choice.

Scenario 2: You qualify for the Lilly savings card. Eli Lilly offers a savings card that reduces copays to as low as $25 monthly for commercially insured patients. If you qualify, brand-name Zepbound at $25 is cheaper than compounded tirzepatide.

Scenario 3: You have a strong preference for FDA-approved medications. Some patients are uncomfortable with compounded medications regardless of cost. If FDA approval is a priority, brand-name is the only option.

Scenario 4: You have difficulty with self-injection. Compounded tirzepatide requires drawing the dose from a vial with a syringe. Mounjaro and Zepbound come in pre-filled pens with automatic injection. If you have dexterity issues, vision impairment, or severe needle phobia, the pen is easier.

Scenario 5: You're traveling internationally frequently. Compounded tirzepatide vials require refrigeration and can be difficult to transport through customs (you need a prescription letter, and some countries don't recognize U.S. compounded medications). Pre-filled pens are easier to travel with and more widely recognized.

Scenario 6: Your provider strongly prefers brand-name. Some endocrinologists and bariatric specialists prefer to prescribe FDA-approved medications and are uncomfortable prescribing compounded versions. If your provider won't prescribe compounded tirzepatide, you'd need to switch to a telehealth provider, which may not be your preference.

The decision framework: If your out-of-pocket cost for brand-name is under $150 monthly and you value convenience and FDA approval, choose brand-name. If your out-of-pocket cost is over $300 monthly and you're comfortable with compounded medications, choose compounded.

The 503A vs 503B decision tree

When ordering compound tirzepatide online, you'll receive medication from either a 503A pharmacy or a 503B outsourcing facility. Here's how to decide which matters for your situation.

Choose a platform that uses 503B if:

• You want the highest level of regulatory oversight (FDA inspection, cGMP standards)
• You're comfortable paying slightly more ($20 to $50 monthly premium) for that oversight
• You have a history of medication allergies or sensitivities and want batch-to-batch consistency
• You're using tirzepatide long-term (12+ months) and want supply chain stability

Choose a platform that uses 503A if:

• You want the lowest cost option
• You're comfortable with state-level oversight (most states have rigorous inspection standards)
• You prefer supporting smaller, local compounding pharmacies
• You need dose customization that 503B facilities may not offer

When it doesn't matter: For most patients, the practical difference between a well-run 503A pharmacy and a 503B facility is minimal. Both produce sterile, properly dosed tirzepatide if they follow standards. The quality difference is smaller than the quality difference between individual 503A pharmacies.

The question to ask: "Which pharmacy will fill my prescription, and what accreditation do they hold?" Look for PCAB accreditation (for 503A) or FDA registration (for 503B). If the platform won't disclose the pharmacy, that's a red flag.

What happens if the FDA removes tirzepatide from the shortage list

The FDA updates the drug shortage database monthly. If Eli Lilly resolves its manufacturing constraints and the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop preparing compounded tirzepatide within 30 days.

What triggers removal from the shortage list:

• Lilly reports to the FDA that it can meet current demand
• The FDA verifies that all doses of Mounjaro and Zepbound are available without backorder
• The shortage is officially resolved

What happens to your prescription:

• Your compounding pharmacy will notify you that they can no longer fill tirzepatide prescriptions
• You'll need to transition to brand-name Mounjaro or Zepbound (if you have a prescription and insurance coverage)
• Telehealth platforms will pivot to prescribing brand-name or will stop offering tirzepatide

How much notice you'll get: Compounding pharmacies are required to stop within 30 days of the shortage resolution. Most telehealth platforms will notify patients 2 to 4 weeks in advance and offer transition support.

The likelihood in 2026: Eli Lilly stated in its Q4 2025 earnings call that tirzepatide supply constraints will persist through at least Q3 2026. The company is building new manufacturing capacity, but it won't come online until late 2026 or early 2027. The FDA shortage designation is likely to remain in place through the end of 2026.

What to do now: If you're using compounded tirzepatide and want continuity, ask your provider about a backup plan. Some patients pursue brand-name prior authorization in parallel so they have coverage if compounding becomes unavailable. Others plan to transition to compounded semaglutide (which has a separate shortage designation) if tirzepatide compounding ends.

FAQ

Is compound tirzepatide legal to order online? Yes, as long as it's prescribed by a licensed provider and dispensed by a licensed U.S. compounding pharmacy. Tirzepatide is currently on the FDA drug shortage list, which permits compounding. Ordering from overseas sources or websites that don't require a prescription is illegal.

How much does compound tirzepatide cost online? Most telehealth platforms charge $179 to $499 per month, depending on dose and whether consultations are included. This is significantly less than the $1,000+ monthly cost of brand-name Mounjaro or Zepbound without insurance.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is prepared by a compounding pharmacy, not manufactured by Eli Lilly. It's delivered in a vial that requires drawing doses with a syringe, not a pre-filled pen. It's not FDA-approved and hasn't undergone the same clinical trials.

Do I need a prescription for compound tirzepatide? Yes. Legitimate telehealth platforms require a consultation with a licensed provider who writes a prescription. Websites that sell tirzepatide without a prescription are not operating legally.

How long does it take to receive compound tirzepatide after ordering? Typically 7 to 14 days from initial intake to delivery. The provider review takes 1 to 3 days, pharmacy fulfillment takes 3 to 5 days, and shipping takes 2 to 5 days depending on your location.

Can I use insurance to pay for compound tirzepatide? Most insurance plans don't cover compounded medications. Compounded tirzepatide is typically paid out-of-pocket. Some HSA and FSA accounts can be used for payment, but check with your account administrator.

What's the difference between 503A and 503B pharmacies? 503A pharmacies are traditional compounding pharmacies regulated by state boards. 503B outsourcing facilities are FDA-registered and inspected, following higher manufacturing standards. Both can legally compound tirzepatide during the shortage.

Is compound tirzepatide safe? When prepared by a licensed, accredited compounding pharmacy following sterile compounding standards, compounded tirzepatide has a safety profile similar to brand-name products. The risk comes from illegitimate sources that don't follow quality standards. Always verify the pharmacy's license and accreditation.

Can I travel with compound tirzepatide? Yes, but you'll need to keep it refrigerated and carry a copy of your prescription. TSA allows syringes and injectable medications in carry-on bags. International travel may require additional documentation, and some countries don't recognize U.S. compounded medications.

What happens if I have side effects from compound tirzepatide? Contact your prescribing provider immediately through the telehealth platform. Common side effects (nausea, diarrhea, constipation) are usually managed by dose adjustment or supportive care. Serious side effects (severe abdominal pain, vision changes, allergic reactions) require emergency medical attention.

How do I know if a telehealth platform is legitimate? Check that the platform discloses its pharmacy partner, requires a licensed provider consultation, has verifiable business registration, accepts standard payment methods, and has third-party reviews. Avoid platforms that ship from overseas, don't require prescriptions, or only accept cryptocurrency.

Can I switch from brand-name Mounjaro to compounded tirzepatide? Yes, with your provider's guidance. The dosing is the same, but the delivery method differs (pen vs vial and syringe). Your provider will ensure you understand how to draw and inject the compounded version before switching.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
4. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2025.
5. National Association of Boards of Pharmacy. Survey of Pharmacy Law. 2025 Edition.
6. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
7. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. Current through 2025 amendments.
8. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. Revised 2024.
9. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight. Diabetes Care. 2023.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Professional Compounding Centers of America. State Compounding Pharmacy Regulations Report. 2025.
12. LegitScript. Telehealth Certification Standards for GLP-1 Prescribing. Updated January 2026.
13. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2026.
14. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.